Orasure Technologies--Form 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 17, 2003

 

 

OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

 

DELAWARE

(State or Other Jurisdiction of

Incorporation or Organization)

  

001-16537

(Commission file number)

  

36-4370966

(I.R.S. Employer

Identification Number)

 

220 East First Street

Bethlehem, Pennsylvania 18015-1360

(Address of principal executive offices)

 

(610) 882-1820

(Registrant’s telephone number, including area code)

 

Item 5 – Other Events and Regulation FD Disclosure.

 

OraSure Technologies, Inc. (the “Company”) issued a press release on November 17, 2003, announcing that it will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for the Company’s OraQuick® Rapid HIV-1 Antibody Test. The information contained in the press release is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

 

Item 7. Financial Statements and Exhibits

 

(c) Exhibits

 

Exhibit Number
   

Description

99

    Press Release dated November 17, 2003, announcing that OraSure Technologies, Inc. will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for its OraQuick® Rapid HIV-1 Antibody Test.

Signatures

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

       

OraSure Technologies, Inc.

Date: November 17, 2003       By:   /s/  JACK E. JERRETT
         
               

Jack E. Jerrett

Senior Vice President, General Counsel

and Secretary

 

 

 

Index to Exhibits

 

Exhibit Number
   

Description

99

    Press Release dated November 17, 2003, announcing that OraSure Technologies, Inc. will be submitting additional data to the U.S. Food and Drug Administration in support of an HIV-2 claim for its OraQuick® Rapid HIV-1 Antibody Test.